2025/26

Bionativa

BIOFTA

OPHTHALMOLOGY

DRY EYE
OCULAR INFLAMMATION
GLAUCOMA
AGE RELATED MACULAR DEGENERATION

Bionativa

MADE IN ITALY, INSPIRING GLOBALLY

Originating from Biodue SpA's Own Brands Division, Bionativa continues its legacy of innovation in medical devices, cosmetics and dietary supplements, rooted in Tuscany's research and production excellence.

PHARCOS

AGEX by PHARCOS

Fitopreparatori Italiani®

BIOFTA

RIVER PHARMA

I.P. FARMA

EFFECTIVE AND SAFE PRODUCTS THROUGH SCIENTIFIC RESEARCH

In **Bionativa**, continuous innovation in product development is supported by scientific research in collaboration with leading research institutions. This approach allows us to create state of the art products focused on achieving effective outcomes, utilizing raw materials of the highest quality and meticulous processes.

- *380+ Products*
- *120+ Product brands, active ingredients and technologies*
- *10 Patents registered globally*
- *30+ R&D Projects annually*
- *40+ Scientific studies with 2,000+ participants*

OUR BRANDS

Bionativa unites leading brands in the Health & Beauty sectors under one corporate ethos, focused on the specifics of each area while sharing a common mission: to value professional advice in a constantly evolving market.

PHARCOS · *Dermatology and Cosmetics*
AGEX · *Aesthetic Medicine*
FITOPREPARATORI ITALIANI · *Proctology and Gastroenterology*
BIOFTA · *Ophthalmology*
RIVER PHARMA · *Orthopedics, Neurology*
IP FARMA · *Otorhinolaryngology, Gynecology, Pediatrics, Urology, Pneumology and General Surgery*

BIOFTA
SOLUZIONI OFTALMICHE

Since 2007, Biofta has been at the forefront of research and development into innovative products for ophthalmology, becoming a reference point for Italian ophthalmologists. Medical devices for eye care and well-being, targeted dietary supplements for each eye segment, cosmetics for ophthalmic use, and specific medications for major eye diseases.

CORNEIAL MED

Eye drops indicated to relieve eye redness, irritation, fatigue, itch and dryness also due to blepharitis, trauma and in the post-operative course of ocular surface surgery (cataract, refractive, IVT, etc.).

- Conjunctivitis prophylaxis
- Keratitis
- Blepharitis
- Dacryocystitis
- Meibomites
- Eye trauma
- Pre/post surgery

ACTIVE SUBSTANCES

PHMB

Has an alternative mechanism of action, thanks to its ability to enter bacterial cells, stop cell division and condense chromosomes, thus suggesting a possible solution to antibiotic resistance. In addition,it has a broad spectrum of action, excellent tolerance and low risk profile.

HIGHLY CROSS-LINKED HYALURONIC ACID

Increases the residence time, increasing the antimicrobial efficacy of PHMB. It protects, repairs and lubrificates the eye surface. Highly cross-linked hyaluronic acid, compared to other cross-linked or linear hyaluronic acid, is more resistant to degradation.

Outperformed competitors in activity against Pseudomonas aeruginosa and Escherichia coli

MEDICAL DEVICE Class IIB

10 ml drops

RRP in Italy:
€ 23.00

IN VITRO COMPARATIVE STUDY

STERILE A

DOSAGE

Instill 1-2 drops of the product in each eye.
It is possible to use the product every day, even several times a day as needed and even while wearing contact lenses.

INGREDIENTS

POLYHEXAMETHYLENE BIGUANIDE: 0.0005%; CROSS-LINKED SODIUM HYALURONATE 0.2%; HPMC 0.2%; DISODIUM EDETATE, BORATE BUFFER, SODIUM CHLORIDE, EXCIPIENTS AND PURIFIED WATER UP TO 100%.

PHMB maintains an in vivo disinfectant capacity and strongly reduces conjunctival bacterial load

From Bench to Application: Evaluating the In Vitro and In Vivo Efficacy of a Polyhexamethylene Biguanide and Cross-Linked Hyaluronic Acid-Based Antiseptic Solution

qr.bionativa.net/cornMed

F. D'Oria, G. Petruzzella, E. D'Ambrosio, F. Pignatelli, G. Addabbo, G. Alessio

RESULTS

Corneial MED® demonstrated a fungistatic effect against C. albicans and A. fumigatus, while it exhibited limited activity against A. flavus. The tested solution effectively reduced bacterial load within minutes, outperforming competitor ophthalmic solutions in activity against P. aeruginosa and E. coli. Conjunctival swabs indicated a significant reduction in bacterial load post-treatment, confirming the solution's efficacy in reducing potential ocular pathogens.



CONCLUSIONS

These findings highlight the potential of PHMB-based antiseptic solutions as a viable alternative to traditional disinfectants, particularly for preoperative prophylaxis and infection control. Further clinical trials are needed to confirm long-term safety and efficacy. The combination with cross-linked hyaluronic acid not only enhances tolerability but also extends antimicrobial action, making it a promising candidate for ophthalmic disinfection.



Efficacy of CORNEIAL MED in reducing the ability of Acanthamoeba castellani to adhere to the corneal epithelium.

Gaiker. Member of Basque Research & Technology Alliance. Zamudio, Spagna.

METHODS

Human corneal epithelium (HCE) cells were cultured in vitro and infected with Acathamoeba.

- PLATE A: infection with Acanthamoeba.
- PLATE B: infection with Acanthamoeba and subsequent inoculation with Corneial Med
- PLATE C: infection with Acanthamoeba and at the same time inoculation with Corneial Med

The adhesion of Acanthamoeba to epithelial cells was assessed by light microscopy. (Yellow arrows indicate Acanthamoeba adhering to cells).







RESULTS

PLATE A: Acanthamoeba adhered to the corneal epithelial cells.
PLATE B: Corneial Med inoculated subsequent to infection reduced Acathamoeba adhesion to corneal epithelial cells.
PLATE C: Corneial Med inoculated at the same time as the infection reduced the adhesion of Acathamoeba to the corneal epithelial cells

CONCLUSIONS

Corneial Med was effective in reducing the adhesion of Acanthamoeba to the corneal epithelium and thus preventing its infection.

CORNEIAL EYE DROPS

Adjuvant eye drop solution for the prevention of red and tired eyes. Suitable for those who suffer from dry eyes, poor tearing and redness due to external agents and conditioned by the use of contact lenses.

- Inflammatory conjunctivitis or cheratoconjunctivitis
- Adverse environmental conditions
- Video terminal operators
- Contact lens wearers
- Allergic conjunctivitis

ACTIVE SUBSTANCES

GLYCEROPHOSPHOINOSITOL *(GPI)*
Anti-inflammatory and decongestant properties. Cortisone-like action.

HYALURONIC ACID 0.2%
Mucoadhesive and viscoelastic properties. Protects, repairs and lubricates the eye surface.

NATURAL EXTRACTS *(Echinacea purpurea - Euphrasia officinalis)*
Anti-inflammatory, cicatrizing and decongestant properties.
Antimicrobial and immunostimulant action.

***Anti-inflammatory, cortisone-like* action**

CORNEAL PATHOLOGIES

MEDICAL DEVICE Class IIB

10 ml drops

RRP in Italy:
€ 23.00

CLINICAL STUDY

STERILE | A
BAC FREE

DOSAGE
Instill 1-2 drops of the product directly in the eye, 2-3 times daily or as prescribed by a doctor.

INGREDIENTS
POLYHEXAMETHYLENE BIGUANIDE: 0.00023%; SODIUM HYALURONATE 0.2%; HPMC 0.2%; EUPHRASY, ECHINACEA, GPI 0.01%, DISODIUM EDETATE, BORATE BUFFER, SODIUM CHLORIDE, EXCIPIENTS AND PURIFIED WATER UP TO 100%.

The drops help avoid the serious side effects of corticosteroids and the occurrence of bacterial resistance

Ocular Surface Failure in Urban Syndrome

M. Antonini, D. Gaudenzi, S. Spelta, G. Sborgia, M. Poddi, A. Micera, R. Sgrulletta, M. Coassin, A. Di Zazzo

qr.bionativa.net/cornDrops

RESULTS

- An **improvement in ocular surface features markers** and also an improvement in the production and quality of tears by a significant increase in the different trial times of T-BUT and the Schirmer test (Fig 1).
- An **improvement of symptoms of acute and chronic irritation** reported by patients over time, as also confirmed by the validated survey on ocular surface discomfort (OSDI), that statistically improves over time (Fig 2).
- A **significant reduction in corneal damage** is obvious in these patients (T1), especially in the subgroup of patients diagnosed with corneal abrasion who show a rapid increase of symptoms already at time T2, but also a resolution of the inflammatory state and healing within 1 month, time T2 (Fig 3).

CONCLUSIONS

CORNEIAL® eye drops shows a dual **ANTI-INFLAMMATORY AND ANTISEPTIC ACTION**, without limiting the healing of the corneal epithelium and the processes of restitutio ad integrum. If effectively applied in a broad spectrum of conjunctivitis and keratoconjunctivitis, the drops help **AVOID THE SERIOUS SIDE EFFECTS OF CORTICOSTEROIDS AND THE OCCURRENCE OF BACTERIAL RESISTANCE** due to empirical antibiotic therapies, which are often not followed upon medical advice.

Fig 1



Fig 2



Fig 3



CORNEIAL SPRAY

Indicated for irritation of the eyelid area which often accompanies dry eyes, blepharitis and other common eye diseases. The formulation is able to restore the lipid component of the epidermis eyelid and maintain the correct hydration. The recovery of hydrolipidic balance resolves the symptoms of burning and itching of the eyelid and thus reduces the swelling and edema resulting from continuous chafing of the sore eyelid.

MEDICAL DEVICE CLASS I

15 ml spray

RRP in Italy:
€ 20.00

BIBLIOGRAPHIC EVIDENCE

FENOSSIETANOL FREE

- Dry eye
- Meibomian gland dysfunction
- Blepharitis
- Chalazion
- Burn
- Itching
- Swelling
- Inflammation and erythema of the periocular area

ACTIVE SUBSTANCES

JOJOBA OIL
Natural mixture of esterified meibum-like waxes (Simmondsia chinensis) restoration of non-polar surface lipid layer.

TREHALOSE
Prevention and repair of epithelial and photo-induced (UVA/UVB) damage.

TERPINEN-4-OLO
Active component of Tea Tree Oil. Antibacterial and antinflammatory activity.

LIPOSOMES
Nanotechnology for carryng jojoba oil and trehalose. Restoration of deep polar layer.

HOW TO USE

Spray on the closed eyelids from a distance of approx. 18-20 cm, holding the spray in a front-lateral position.
Spray 1-2 times onto each eyelid at least 2-3 times daily, before makeup and/or after cleansing, especially in the evening.

INGREDIENTS

LIPOSOME CONTAINING TREHALOSE, JOJOBA OIL, SODIUM HYDROXYMETHYLGLYCINATE, DISODIUM EDTA, SODIUM CHLORIDE, POLYSORBATE, TERPINEN-4-OL, BUFFER, WATER Q.S.

> ***Restores the lipid component of the epidermis eyelid and maintains the correct hydration***

> **Terpinen-4-ol is effective in *killing demodex mites***

Terpinen-4-ol is the Most Active Ingredient of Tea Tree Oil to Kill Demodex Mites

qr.bionativa.net/tTreeOil

Sean Tighe, Ying-Ying Gao, Scheffer C. G. Tseng - Transl Vis Sci Technol, 2013

RESULTS

All ingredients exhibited a dose-dependent killing effect. Besides Terpinen-4-ol, the order of relative potency did not correlate with the order of relative abundance in TTO for the remaining 12 ingredients. Terpinen-4-ol was the most potent ingredient followed by α-Terpineol, 1,8-Cineole and Sabinene. Terpinen-4-ol, the most abundant ingredient in TTO, was more potent than TTO at equivalent concentrations and its killing effect was even observable at a mere concentration of 1%. Terpinen-4-ol exhibited a significant synergistic effect with Terpinolene, but an antagonistic effect with α-Terpineol in killing mites (both $P < 0.05$). In vivo, Terpinen-4-ol was shown to eradicate mites.

CONCLUSIONS

The above finding suggests that deployment of Terpinen-4-ol alone should enhance its potency in killing Demodex mites by reducing the adverse and antagonistic effects from other ingredients in TTO.



Figure 1. In vivo effect of Terpinen-4-ol on eradication of Demodex mites. Before treatment, cylindrical dandruff was found in many lashes (A, arrow) and mites were detected under microscopic examination of the epilated lash (B). After treatment with the T4O lid cleanser, the lashes were clean (C) and no mite was detected in the epilated lash (D).

Protective effect of trehalose-loaded liposomes against UVB-induced photodamage in human keratinocytes

qr.bionativa.net/trehalose

Enzo Emanuele, Marco Bertona, Fabian Sanchis-Gomar, Helios Pareja-Galeano, Alejandro Lucia - Biomed Rep., 2014

ABSTRACT

Trehalose, a naturally occurring non-reducing disaccharide, is known to act as a major protein stabilizer that can reduce ultraviolet B (UVB)-induced corneal damage when topically applied to the eye. However, due to the low skin permeability of trehalose, which makes the development of topical formulations difficult, its use as a skin photoprotective agent has been limited. Previous findings demonstrated that liposomes may significantly improve the intracellular delivery of trehalose. Therefore, the present study aimed to assess the protective effects of trehalose-loaded liposomes against UVB-induced photodamage using the immortalized human keratinocyte cell line, HaCaT. The effects were also compared to those of the common skin photoprotective compounds, including L-carnosine, L-(+)-ergothioneine, L-ascorbic acid and DL-α-tocopherol. The levels of cyclobutane pyrimidine dimers, 8-hydroxy-2'-deoxyguanosine and protein carbonylation in HaCaT cells were used as biological markers of UVB-induced damage. Compared to other compounds, trehalose-loaded liposomes showed the highest efficacy in reducing the levels of the three markers following UVB irradiation of HaCaT cells (all $P<0.001$ when compared to each of the four other photoprotective compounds). Therefore, these findings indicate that there may be a clinical application for trehalose-loaded liposomes, and further studies should be performed to assess the potential usefulness in skin photoprotection and the prevention of non-melanoma skin cancer.

CITINERV PLUS

Citinerv Plus is a food supplement of Vitamins (B1, B6, B12 and D3) with Citicoline sodium, Glutathione and essential fatty acids (Omega 3 and Omega 6) present in Hemp Seed Oil. Vitamins B1, B6 and B12 contribute to the normal functioning of the nervous system.



OPTIC NEUROPATHY

FOOD SUPPLEMENT
30 x 707 mg softgel
RRP in Italy:
€ 28.00

2 CLINICAL STUDIES

GLUTEN FREE
PATENT ON
FORMULATION N° 102022000008894

- Amblyopia
- Glaucoma
- Neuritis and trigeminal neuralgia
- Herpetic keratitis
- Neuro-ophthalmological diseases

ACTIVE SUBSTANCES

CITICOLINE
Is a molecule with antiapoptotic and neurotrophic activity.

GROUP B VITAMINS
Play a part in the normal functioning of the nervous and visual systems.

VITAMIN D3
Has a key role in regulating the physiological processes involved in the inflammation and degeneration of neuronal tissue. The insufficiency of vitamin D may affect the severity of glaucoma as a result of increased inflammation and neurodegeneration.

GLUTATHIONE
Reduces oxidative stress, with anti-inflammatory, neuro-protective and antidepressant action.

CANNABIS SATIVA L. SEED OIL
Is a "super food" with powerful antioxidant, immunomodulating, anti-inflammatory, hypotensive and neuro-protective properties.

DOSAGE AND INSTRUCTIONS FOR USE
It is recommended to take 1 soft gel up to 4 times per day, for at least 4 months. Do not exceed the recommended daily dose.

COMPOSITION
PEARL CONTENT: CITICOLINE SODIUM, HEMP SEED OIL (CANNABIS SATIVA L.), GLUTATHIONE, SUNFLOWER OIL, EMULSIFIERS: MONO- AND DIGLYCERIDES OF FATTY ACIDS, SUNFLOWER LECITHIN; ANTI-CAKING AGENT: SILICON DIOXIDE, THIAMINE HYDROCHLORIDE, VITAMIN B12 TIT. 0.1% (CYANOCOBALAMIN, MALTODEXTRIN, ACIDULANTS: CITRIC ACID, TRISODIUM CITRATE), PYRIDOXINE HYDROCHLORIDE, VITAMIN D3 OF PLANT ORIGIN (CHOLECALCIFEROL, MEDIUM-CHAIN TRIGLYCERIDES, ANTIOXIDANT: D-α-TOCOPHEROL). OUTER CASING: GELATIN, RESISTANCE AGENT: SORBITOL, COLOURS: E172, E133.

NUTRITIONAL INFORMATION

	for 1 softgel	%RNV*/ 4 softgels
Citicoline sodium	250 mg	
Hemp seed oil	242,5 mg	
Glutathione	25 mg	
Thiamine (vit. B1)	0,7 mg	254,5%
Pyridoxine (vit. B6)	0,5 mg	142,9%
Cyanocobalamin (vit. B12)	0,75 mcg	120%
Cholecalciferol (vit. D3)	10 µg	800%

*%RNV = percentage reference nutritional value (EU Reg. 1169/2011)

Stabilization/improvement** of visual parameters in patients with **optic neuropathy

***Higher bioavailability** than other pharmaceutical forms*

Efficacy of Citinerv® Plus on glaucomatous optic disease with computerized campimetry

qr.bionativa.net/citPlus

Dr. Dario Iannaccone

RESULTS

Positive effect in 90% of cases.

At the final observation, performed on day T1, there was an improvement of the controlled clinical and perimetric parameters in 36 eyes (60%) and/or at least stabilization of the same in 18 eyes (30%), while only 6 eyes (10%) showed worsening.

In particular, there was an average improvement in Mean Deviation of 0.86 dB (from -3.88 to -3.02 on average), and in Pattern Standard Deviation of 3.62 (from an average of 15.59 to 11.97).

Mean Visual Acuity (in tenths) also increased in a statistically significant manner from 0.76 (TO) to 0.88 (T1).



CONCLUSIONS

Evidently, the mix of Citicoline, B-complex (Vit. B1, B6, and B12), Glutathione, and Omega 3 fatty acids (Hemp Seed Oil) has shown a synergistic effect, able to stabilize/improve visual parameters in patients with optic neuropathy.





Temporal dynamics of plasma choline levels following administration of different citicoline supplement formulations

Susana López-Ortiz, José Pinto-Fraga, Alejandro Santos-Lozano, Simone Lista, Piercarlo Minoretti

AIMS

To compare plasma choline levels following identical doses of citicoline across four different supplement formulations.

METHODS

Twenty healthy adults received a single 250 mg dose of citicoline as either tablet, syrup, sachet powder, or softgel capsule in a randomized design.

RESULTS

All formulations significantly increased plasma choline levels from baseline. The softgel demonstrated superior overall bioavailability (AUC0-12h: 152.44 µM·h) and extended-release properties, maintaining elevated levels at 12 hours (11.99 µM, 14.7% above baseline). No adverse events were reported.

CONCLUSIONS

Supplement formulation may significantly influence citicoline bioavailability. The softgel offers superior extended-release characteristics.

Parameter	Tablet	Syrup	Sachet	Softgel	p value
AUC0-12h (uM·h)	139,26	143,08	141,25	152,44	<0,05
AUC0-∞, (uM·h)	793,41	697,39	562,42	1166,05	<0,05



ASTENOMIRT EYE DROPS

Eye drops specifically designed to reduce visual stress and protect the surface of the eye from blue light emitted by electronic devices

- Prolonged exposure to sunlight or electronic devices
- Eye strain
- Dryness and burning caused by computer vision syndrome

ACTIVE SUBSTANCES

HYALURONIC ACID 0.15%
Protects, repairs and lubricates the surface of the eye

ANTHOCYANIDINS *(Vaccinium Myrtillus)*
Reduces ciliary muscle fatigue, protects against blue light

FLAVONOIDS AND TANNINS *(Euphrasia Officinalis/Hamamelis Virginiana/ Camomilla Recutita)*
Anti-inflammatory and antioxidant properties.

OCULAR DISCOMFORT

MEDICAL DEVICE Class IIB

10 ml drops

RRP in Italy:
€ 22.00

CLINICAL STUDY

STERILE
HYALURONIC ACID HCXL 0.2%
HIGH VISCOELASTICITY
HIGH MOLECULAR WEIGHT 3.6 M Da
PRESERVATIVE FREE

FREQUENCY OF USE
Instill 2/3 drops per eye, 2-3 times a day or according to the doctor's opinion

COMPOSITION
HYALURONIC ACID 0,15%, GLYCERIN 0,2%, VACCINIUM MYRTILLUS DISTILLED WATER, HAMAMELIS VIRGINIANA DISTILLED WATER, CHAMOMILLA RECUTITA DISTILLED WATER, EUPHRASIA OFFICINALIS DISTILLED WATER, SODIUM CHLORIDE, SODIUM PHOSPHATE DIBASIC DODECAHYDRATE, SODIUM PHOSPHATE MONOBASIC MONOHYDRATE, PURIFIED WATER.

Reduces visual stress and protects the ocular surface

ASTENOMIRT VIALS

Food supplement specifically designed to reduce visual fatigue and improve visual function in patients with accommodative and occupational asthenopia.

FOOD SUPPLEMENT
15 x 10 ml vials
RRP in Italy:
€ 22.00

OBSERVATIONAL STUDY

GLUTEN FREE

- Juvenile myopia and/or high myopia
- Hyperopia
- Early stages of presbyopia
- Visual fatigue from videoterminals or other digital media
- Night blindness

ACTIVE SUBSTANCES

CROCETIN *(Crocus sativus e.s. tit. 30%)*
Increases blood flow to the ciliary muscles

MYRTOPURE 36® *(Vaccinium myrtillus e.s. tit. 36%)*
Promotes rhodopsin regeneration in the retina

TAURINE
Improves axonal flow at the synapses.

DOSAGE
One vial per day.

COMPOSITION
WATER, FRUCTOSE, TAURINE, MYRTO PURE 36® (VACCINIUM MYRTILLUS L.) FRUIT DRY EXTRACT TIT. MIN. 36% HPLC METHOD IN ANTHOCYANINS (BLUEBERRY, MALTODEXTRIN), WILD BERRY FLAVORING, PRESERVATIVES: POTASSIUM SORBATE, SODIUM BENZOATE; SAFFRON (CROCUS SATIVUS L.) STIGMA DRY EXTRACT TIT. 2% IN SAFRANAL AND 2% IN CROCIN (SAFFRON, MALTODEXTRIN). ACIDITY REGULATOR: CITRIC ACID.

Reduces fatigue and improves visual function

ALTIAL PLUS

OCULAR DISCOMFORT

Ophthalmic lubricating solution based on cross-linked hyaluronic acid, formulated for the treatment of ocular discomfort.

MEDICAL DEVICE Class IIB

10 ml drops

RRP in Italy:
€ 23.00

CLINICAL STUDY

STERILE

HYALURONIC ACID HCXL 0.2%

HIGH VISCOELASTICITY

HIGH MOLECULAR WEIGHT 3.6 M Da

- Prolonged exposure to sunlight
- Uv radiation and ionizing radiation
- Living/working in air-conditioned environments
- Prolonged use of computers, smartphone, tv
- Contact with detergents
- Contact lens wearers
- Post-surgical discomfort
- Mild to severe eye dryness (Sjiogren)

ACTIVE SUBSTANCES

HYALURONIC ACID *(highly cross-linked)*

More resistant to degradation compared to other cross-linked hyaluronic acids. Therefore it shows greater stability and a longer residence time at corneo-conjunctival level. It is useful for the treatment of patients with dry eyes, even in severe forms.

DOSAGE AND INSTRUCTIONS FOR USE

Instill 1-2 drops of product directly in the eye when needed, even several times a day.

COMPOSITION

POLYHEXAMETHYLENE BIGUANIDE: 0.00023%; CROSS-LINKED SODIUM HYALURONATE 0.2%; HPMC; DISODIUM EDETATE, BORATE BUFFER, SODIUM CHLORIDE, EXCIPIENTS AND PURIFIED WATER UP TO 100%.

Remarkable results in the treatment of mild dry eye and moderate dry eye

Evaluation of the efficacy of a highly cross-linked hyaluronic acid eye drop (Altial Plus) in the treatment of mild/moderate dry eye compared with a linear hyaluronic acid formulation

Dr. Tiziana Tritto and Prof. Martino Mariano Tritto

qr.bionativa.net/altPlus

EQUIPMENT AND METHODS

Population 40 patients (20 women + 20 men: 80 eyes), aged between 20 and 60:
- 20 patients with mild dry eye (40 eyes)
- 20 patients with moderate dry eye (40 eyes)

Inclusion criteria were age between 30 and 70 years and a history of at least 3 months of dry eye symptoms, referable to moderate dry eye (Dry Eye Workshop [DEWS] stage 2 classification with TF-BUT < 10 s, Schirmer score < 10 mm).
The study included 4 visits: an initial enrollment visit (T0), 2 follow-up visits (one after 7 days, another at 30 days), and a final study visit (after 60 days).
All patients performed 3 administrations a day for both months, with Linear Hyaluronic Acid 0.2% high PM (HA) only in the Right Eye (RE) and Cross-linked Hyaluronic Acid 0.3% high PM (HA-CXL) in the Left Eye (LE).

EQUIPMENT USED:

1. OSDI (benchmark questionnaire)
2. A Digital pH meter (pH between 7.2 and 7.4) or bibula paper
3. An Osmolarity Meter (or Polarimeter).
4. An EASYTEARview Plus
5. Schirmer's Tests I and II
6. TBUT (Tear break-up time test)
7. Blink frequency per minute.

FINAL REMARKS

The 0.3 % concentration and high molecular weight plus the three-dimensional composition of HA-CXL gives remarkable results in both Mild Dry eye and Moderate Dry eye compared to linear Hyaluronic Acid.



Schirmer II Test Results, RE treated with (HA) and LE treated with (HA-CXL) in MODERATE DRY eye

TAURETINA

Dietary supplement indicated to supplement substances physiologically present in high amounts in the retina such as lutein and zeaxanthin.

FOOD SUPPLEMENT

30 x 500 mg acid-resistant capsules

RRP in Italy:
€ 24.00

CLINICAL STUDIES

- Dry and wet AMD
- Vasculopathy
- Posterior uveitis
- Proliferative vitreoretinopathy
- Intravitreal therapies
- IVT therapy adjuvant
- Post operative EMC

ACTIVE SUBSTANCES

ZINC
Helps to maintain normal eyesight and, associated with copper and coenzime Q10, protects cells against oxidative stress.

TAURINE
At retinal level is the most important aminoacid after glutammate and has a multiplicity of effects, recent studies have shown that taurine may be useful in AMD.

CURCUMIN
Has antioxidant and antiflammatory properties. Thanks to the patented association with hydroxy propyl methyl cellulose, it has allowed a significant improvement in absorption at the gastrointestinal level.

CHOLECALCIFEROL
Can prevent the risk of developing early and intermediate AMD by inhibiting oxidative stress, inhibiting extracellular amyeloid deposits and inhibiting macrophage activation.

LUTEIN and ZEAXANTHIN
Are physiologically present in the retina in high quantities and have an antioxidant and optical filter action.

Proven effective in both prevention and treatment of an early form of atrophic, age-related macular degeneration

DOSAGE
It is recommended to take one capsule daily or 2, on medical advice. Do not exceed the recommended daily dose.

INGREDIENTS
ZINC GLUCONATE, TAURINE, MARIGOLD (TAGETES ERECTA L.) FLOWERS EXTRACT TIT. MIN. 10% IN LUTEIN ESTERS AND MIN. 4% IN ZEAXANTHIN (MARIGOLD, BULKING AGENTS: MICROCRYSTALLINE CELLULOSE, DIBASIC CALCIUM PHOSPHATE; ANTI-CAKING AGENT: SILICON DIOXIDE, STABILIZERS: TOCOPHEROL-RICH EXTRACT, ASCORBYL PALMITATE), GLUTATHIONE IN LIPOSOMAL FORM TIT. 20% (GLUTATHIONE, SUNFLOWER LECITHIN), BULKING AGENT: DIBASIC CALCIUM PHOSPHATE, ANTI-CAKING AGENT: MAGNESIUM SALTS OF FATTY ACIDS, COENZYME Q10, ANTI-CAKING AGENT: SILICON DIOXIDE, COPPER GLUCONATE, CHOLECALCIFEROL. OUTER CASING: HYDROXYPROPYL METHYL CELLULOSE, GELLING AGENT: GELLAN GUM, COLORING AGENT: YELLOW IRON OXIDE.

NUTRITIONAL INFORMATION

	each capsule	% VNR/ capsule
Taurine	100 mg	
Coenzyme Q10	5 mg	
Zinc	12,5 mg	125%
Copper	0,5 mg	50%
Cholecalciferol (Vit. D3)	10 µg	200%
Marigold ex. tit. min. 10% in lutein and min. 4% in zeaxanthin	100 mg	
Lutein	10 mg	
Zeaxanthin	4 mg	
Liposomal glutathione	50 mg	

Efficacy of anti VEGF IVT therapy combined with Tauretina® in retinal macular edema

qr.bionativa.net/tRetina

Dr. M.C. Mallocci, Prof. M. Fossarello

CONCLUSIONS

In all cases, there was a significant reduction in the number of its performed in one



year; Anti VEGF is therefore the therapy of choice for the control of vascular disease, which, when combined with the use of TAURETINA®, can significantly reduce the average number of injections to be performed.

Efficacy and tolerability of Tauretina® in prolonged treatment, five years on: CASE REPORT

Dr. Bruno Migliore

CLINICAL EXAMINATION

66-year-old woman, hypertensive, smoker, reported non-specific "visual disturbance"
VCC OO 9/10 poor
IOP OO 16 mmHg
FO OO generic "macular dystrophy" visible
Angio OCT OO RPE changes with presence of drusen, no serum or abnormal flows.

TREATMENT PROTOCOL

Tauretina 1 capsule daily (continuous cycles of 3 months of therapy interspersed with 1 month off).

RESULTS AFTER 5 YEARS

Examination requested by rheumatologist for rheumatoid arthritis and Plaquenil therapy for at least two years.
No longer reports any "visual disturbance".
VCC OO 10/10
IOP OD 15 mmHg OS 17 mmHg
FO OO nonspecific angiosclerosis with notes of macular dystrophy
Angio OCT OO shows no noteworthy changes, complete remission of previous changes.

CONCLUSIONS

Administration of Tauretina for five years, as objectified on visus, FO and Angio OCT examination, has proven effective in both prevention and treatment of an early form of atrophic, age-related macular degeneration, despite age, onset of rheumatoid arthritis and Plaquenil therapy.

OFTALDERM WIPES

Cosmetic that can be used for the cleansing of eyelids and eyelashes in any situation requiring an effective and gentle sanitizing action.

- Blepharitis
- Catarrhal conjuntivitis
- Pre-post surgical hygiene
- Removal of squamous residues and make-up

Oftalderm® Wipes is made of soft towels soaked in a creamy formulation that makes the application more comfortable and allows the removal of scaly residue, mucus or make-up. The plant extracts, with their emollient action, moisturize and refresh the eye area by providing relief in case of irritation. The product is particularly useful when hygienising the eye area in cases of high sensitivity, such as after ophthalmic surgery or in the presence of inflammatory and irritative phenomena of eyelid typically associated with secretion. The wipes can be used by contact lens wearers.

ACTIVE SUBSTANCES

TERPINEN 4-OL

Selective antibacterial activity on the main bacteria responsible for eyelid and eyelash infections (stapylococcus aureus, s epidermidis and pseudomonas aeruginosa); Anti-inflammatory activity; Acaricidal activity VS DEMODEX main cause of blepharitis (inflammation of the eyelids).

ECHINACEA ANGUSTIFOLIA

Emollient, anti-inflammatory, re-epithelizing activity.

EYELID HYGIENE

COSMETIC

16 monodose sterile wipes

RRP in Italy:
€ 18.00

BIBLIOGRAPHIC EVIDENCE

STERILE A
PARFUM FREE
OPHTHALMOLOGICALLY TESTED
DERMATOLOGICALLY TESTED ON SENSITIVE SKIN
ALSO FOR CHILDREN AND BABIES

INSTRUCTIONS FOR USE

Open the bag from the precut with clean hands; take out the wipe and massage it gently onto the eyelids and eyelashes, keeping the eyes closed. Use a wipe for each eye, discard the wipe after use. Do not rinse after application.

COMPOSITION

AQUA, CETEARETH-20, CETYL ESTERS, LAURYL GLUCOSIDE, ECHINACEA ANGUSTIFOLIA EXTRACT, 4-TERPINEOL, PROPYLENE GLYCOL, CARBOMER, LAURETH-9, DISODIUM EDTA, TRIETHANOLAMINE, PHENETHYL ALCOHOL, CAPRYLYL GLYCOL.

Effective and gentle sanitizing action + relief in case of irritation

Bionativa S.p.A.
Via Raffaello 15
Loc. Sambuca Val di Pesa
50028, Barberino Tavarnelle (FI)
ITALY
bionativa.net

biofta.com